帕罗西汀联合丁螺环酮治疗焦虑症对照研究

A control study of paroxetine combined with buspirone in the treatment of anxiety disorder

目的探讨帕罗西汀联合丁螺环酮治疗焦虑症的l艋床疗效和安全性。方法将86例焦虑症患者随机分入两组，观察组44例，口服帕罗西汀联合丁螺环酮治疗，对照组42例，口服帕罗西汀治疗，观察8周。于治疗前及治疗4周、8周末采用汉密顿焦虑量表评定临床疗效，并随时记录不良反应。结果治疗后两组汉密顿焦虑量表评分均较治疗前显著下降（P〈0.01），治疗各时段观察组评分较对照组下降更显著（P〈0.01）；治疗8周末，观察组总有效率79．5％，对照组为59．5％，观察组显著高于对照组（χ^2=4．08，P〈0．05）。两组不良反应较轻微，主要表现为头晕、消化道反应、嗜睡等，发生率比较差异无显著性（P〉0.05）。结论帕罗西汀联合丁螺环酮治疗焦虑症效果更显著，且不增加不良反应，安全性高，依从性好，显著优于单用帕罗西汀治疗。

Objective To explore the efficacy and safety of paroxetine combined with buspirone in the treatment of anxiety disorder. Methods Eighty-six anxiety patients were randomly divided into observation group （n=44） taking orally paroxetine combined with buspirone and control group （n=42） doing paroxetine for 8 weeks. Efficacies were assessed with the Hamilton Anxiety Scale （HAMA） at baseline and at the end of the 4^th and 8th week and adverse reactions recorded any time. Results The HAMA scored of both groups lowered more significantly after treatment compared with pretreatment （P〈0.01） and so did those in observation than in control group in each period （P〈0.01） ; total effective rate was respectively 79.5% in observation and 59.5% in control group, the former was significantly higher than the latter at the end of the 8th week （χ^2 =4.08,P〈0.05）. Adverse reactions of both groups were mild and mainly dizziness, digestive tract reactions, lethargy and so on, there were no significant group difference in their incidences （P〉0. 05）. Conclusion Paroxetine combined with buspirone has more notable efficacy in the treatment of anxiety disorder, doesn＇t increase adverse reactions, and has higher safety and better compliance compared with single paroxetine.